相关临床试验
89
16 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1853
进行中（未招募）
8
9.0%
已完成
49
55.1%
尚未招募
8
9.0%
招募中
17
19.1%
终止
2
2.3%
Unknown
5
5.6%
暂无批准数据
- Methaqualone, sold in the 1970s as the brand-name sedative Quaalude, is re-emerging in illicit markets decades after the US banned it in 1984. - Researchers and users interviewed by The Guardian attribute renewed demand largely to the 2013 film The Wolf of Wall Street, which made the drug a pop-culture reference. - Illicit supplies began appearing on darkweb marketplaces around 2018, sourced from producers in South Africa, and expanded on Telegram and Reddit after the pandemic. - The drug carries serious risks: an uncommonly long half-life of up to 60 hours, rapid tolerance, compulsive use linked to a unique GABA receptor binding site, and 117 related deaths in 1980.
- The Aikenhead Centre for Medical Discovery (ACMD), Australia's first hospital-based biomedical engineering research centre, has opened at St Vincent's Hospital in Fitzroy, Melbourne. - The AU$206 million facility brings together clinicians, scientists, and engineers to fast-track medical discoveries into patient benefits using AI, biotechnology, and regenerative medicine. - The centre can accommodate up to 900 researchers, train 300 new doctors annually, and features 3D printing labs, a kinetics lab, engineering workshops, and robotics. - Research will target chronic conditions including epilepsy, cancer, and osteoarthritis, with the goal of translating laboratory discoveries to the bedside faster and more reliably.
- Roche has appointed Mark Dawson, a leading Australian cancer researcher, as the new Head of Pharma Research and Early Development (pRED), effective May 1, 2026. - Dawson joins from the Peter MacCallum Cancer Centre where he led development of first-in-class epigenetic therapies that have reached clinical testing stages. - The appointment comes as Roche faces upcoming patent expiries for blockbuster drugs including Ocrevus, Gazyva/Gazyvaro, and Perjeta. - Dawson will oversee 1,800 scientists across five global pRED locations working on therapeutic compounds from discovery through early clinical trials.
- Scientists have identified the genetic mechanism behind vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but potentially fatal blood clotting condition linked to adenovirus-based COVID vaccines. - The study published in The New England Journal of Medicine found that VITT occurs in individuals with specific DNA variants whose immune cells produce cross-reactive antibodies against both the adenovirus and PF4, a blood clotting molecule. - All 100 VITT patients studied had one of two specific genetic variants, but required an additional genetic mutation in immune cells to develop the dangerous cross-reactive antibodies. - The findings could enable safer design of future adenovirus-based vaccines by engineering around the specific protein region that triggers the problematic immune response.
- Biomodal's duet evoC technology achieved 95% diagnostic accuracy (AUC = 0.95) for stage I colorectal cancer detection through liquid biopsy, significantly outperforming conventional methods that achieved only 66% accuracy. - The breakthrough involves simultaneously distinguishing between two epigenetic markers, 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), in cell-free DNA, revealing previously hidden biological signals critical for early cancer detection. - Research published in Nature Communications Medicine demonstrates that nearly half of examined genomic regions showed activation patterns during cancer progression, with increased 5hmC in early-stage cancers and decreased 5mC in late-stage cancers. - AstraZeneca's validation study confirmed the enhanced sensitivity of biomodal's approach, with Dr. Sophie Kirschner presenting supporting data at the Festival of Genomics and Biodata London 2026.
- Monash University researchers have uncovered the genetic code governing how mutations affect RNA splicing, a critical cellular process for protein production. - The breakthrough enables development of personalized mRNA therapeutics for rare and population-specific diseases previously difficult to treat. - Scientists used the SpliSER tool to analyze millions of splice-sites across 25+ species, revealing patterns that link genetic mutations to disease mechanisms. - The discovery provides a "clear explorable pathway to a cure" for debilitating genetic conditions, with immediate applications expected in therapeutic development.
- Ocrelizumab showed significantly lower MS relapse rates compared to fingolimod (0.06 vs 0.14; p<0.001), natalizumab (0.07 vs 0.10; p<0.001), and alemtuzumab (0.12 vs 0.18; p<0.001) in a multi-registry analysis. - The study analyzed real-world data from over 16,000 patients across three major MS registries, with fingolimod patients showing more than twice the risk of relapse compared to ocrelizumab (HR 2.26, 95% CI 1.98–2.58). - Despite superior relapse control, ocrelizumab showed no differences in progression independent of relapse activity compared to other high-efficacy therapies, suggesting a ceiling effect for disability benefits through relapse suppression alone.
- Proteomics International secured ISO 15189 certification for its Australian laboratory, enabling high-quality clinical testing and supporting the national rollout of its diagnostic suite. - The company launched PromarkerD in August 2025, a blood test that predicts diabetic kidney disease up to four years in advance with 86% accuracy, outperforming standard tests. - PromarkerEso, a blood test for early detection of esophageal cancer, was launched in September 2025, addressing a critical need given the disease's low 20% five-year survival rate. - Additional diagnostic tests including PromarkerEndo for endometriosis and OxiDx for oxidative stress are scheduled for second half 2025 launches, expanding the company's commercial pipeline.
- Melbourne-based Mirugen secured A$4.5 million in seed funding to develop its pioneering cell reprogramming technology targeting retinal diseases. - The company's lead program focuses on treating retinitis pigmentosa by reprogramming Muller glial cells to regenerate lost photoreceptors in the eye. - The therapy platform may also have applications for age-related macular degeneration and Stargardt disease, potentially addressing major causes of blindness worldwide. - Charlotte Casebourne Stock, who previously led Theolytics from inception to clinic, has been appointed as executive chair and acting CEO.
- Australian researchers have identified the first potential prophylactic treatment for HTLV-1, a neglected virus affecting 10 million people globally, using existing HIV antivirals tenofovir and dolutegravir in humanized mouse models. - The study marks the first time any research group has successfully suppressed HTLV-1 transmission in a living organism, with both drugs showing powerful suppression against international and Australian virus strains. - Combination therapy using HIV antivirals with MCL-1 protein inhibitors demonstrated the ability to selectively kill HTLV-1-infected cells, suggesting a potential curative strategy for established infections. - The research team is now in discussions with pharmaceutical companies to include HTLV-1 patients in ongoing HIV drug clinical trials, potentially leading to the first approved pre-exposure prophylaxis for this life-threatening virus.
